科伦药业(002422.SZ)：控股子公司科伦博泰拟实施2025年股份激励计划

Core Viewpoint - Kolun Pharmaceutical (002422.SZ) announced the implementation of a long-term incentive plan for its subsidiary, Sichuan Kolun Botai Biopharmaceutical Co., Ltd. (6990.HK), aimed at attracting and retaining key talent to drive business development and align interests among shareholders, the company, and core personnel [1] Group 1 - The incentive plan will grant restricted stock units, with shares sourced from new H-shares issued by Kolun Botai, existing treasury shares (if any), and shares purchased in the open market by a trustee [1] - The maximum number of shares to be granted under the incentive plan will not exceed 3,500,000 H-shares, which is approximately 1.5% of the total shares of Kolun Botai as of the date of the shareholders' meeting approving the plan [1] - The issuance of new H-shares under the plan will not significantly alter the company's ownership stake in Kolun Botai, which will remain a controlled subsidiary [1]